Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-Current Debt (2016 - 2024)

Historic Non-Current Debt for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2024 value amounting to $34.3 million.

  • Harvard Bioscience's Non-Current Debt fell 289.46% to $34.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $34.3 million, marking a year-over-year decrease of 289.46%. This contributed to the annual value of $30.7 million for FY2023, which is 2861.69% down from last year.
  • Latest data reveals that Harvard Bioscience reported Non-Current Debt of $34.3 million as of Q3 2024, which was down 289.46% from $32.0 million recorded in Q2 2024.
  • In the past 5 years, Harvard Bioscience's Non-Current Debt registered a high of $46.5 million during Q3 2022, and its lowest value of $30.7 million during Q4 2023.
  • For the 5-year period, Harvard Bioscience's Non-Current Debt averaged around $40.5 million, with its median value being $41.1 million (2023).
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 1183.5% in 2022, then plummeted by 2861.69% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Non-Current Debt stood at $46.3 million in 2020, then dropped by 2.57% to $45.1 million in 2021, then fell by 4.62% to $43.0 million in 2022, then dropped by 28.62% to $30.7 million in 2023, then rose by 11.56% to $34.3 million in 2024.
  • Its Non-Current Debt stands at $34.3 million for Q3 2024, versus $32.0 million for Q2 2024 and $31.9 million for Q1 2024.